GLP-1 RAs are currently being explored for use in various new areas, such as cardiovascular disease, non-alcoholic steatohepatitis (NASH), Alzheimer's disease, and chronic kidney disease
Instead, they focus on finding a treatment approach that is safe and tailored to your unique situation
Your care is personalized, provider-reviewed, and designed to support steady progress rather than extreme restrictions
doi:10.1016/S2213-8587(19)30066-X Zinman B, Bhosekar V, Busch R, et al
Beginners should start at 0.04 mg bilaterally (0.08 mg total) and assess response over 3 weeks
Reviews are generally fairly negative, with many customers complaining about unclear pricing